Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 2/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577324 | 0.88 | ESR1 (0.50) | ATMCES2CES1TP53ESR1 | |
| SCHEMBL27523961 | 0.86 | ALDH1A1 (0.44) | ATMALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8672567 | 0.85 | CES1 (0.52) | CES2CES1AKR1B1MAPTALDH1A1 | |
| SCHEMBL451258 | 0.83 | ATM (0.54) | ATMCES2CES1TP53ESR1 | |
| SCHEMBL8994830 | 0.83 | CES2 (0.47) | CES2CES1AKR1B1TP53ESR1 | |
| SCHEMBL6062883 | 0.78 | ALDH1A1 (0.50) | ATMCES2CES1TP53ALDH1A1 | |
| SCHEMBL8475501 | 0.77 | MEN1 (0.55) | CES2CES1TP53MEN1KMT2A | |
| SCHEMBL1254294 | 0.76 | ATM (0.48) | ATMCES2CES1TP53ESR1 | |
| SCHEMBL6985793 | 0.76 | KMT2A (0.53) | CES2CES1MAPTALDH1A1MEN1 | |
| SCHEMBL814927 | 0.74 | CES2 (0.52) | ATMCES2CES1TP53ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VIDASYM, LLC | 2018-11-15 | — | — | US | disclosed |
| EP-2419403-B1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM INC (US) | 2016-09-07 | — | — | EP | disclosed |
| WO-2014085413-A1 | DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VIDASYM, LLC (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2419403-A1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | Vidasym, Llc (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120698-A1 | VITAMIN D RECEPTOR AGONISTS AND USES THEREOF | VIDASYM, LLC (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2001052868-A1 | COMBINATIONS FOR TREATING NEOPLASMS | YU BAOFA (US) | 2001-07-26 | — | — | WO | disclosed |
| US-5508273-A | ARALKYLPHOSPHONATES FOR OSTEOPOROSIS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-4479827-A | WITH TALL OIL | PULEO, ROBIN WARD | 1984-10-30 | — | — | US | disclosed |
| US-4453980-A | INSTANTANEOUS REPAIR OF ROADS AT LOW TEMPERATURES | PULEO, ROBIN WARD | 1984-06-12 | — | — | US | disclosed |
| US-4438020-A | CARBONYLATION, HYDROGENATION | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1984-03-20 | — | — | US | disclosed |
| US-4373960-A | BINDER CONSISING OF ASPHALT, TALL OIL AND A POLYSILOXANE WITH LIMESTOME | PULEO, ROBIN WARD | 1983-02-15 | — | — | US | disclosed |
| US-4361706-A | FROM METHANOL, HYDROGEN AND CARBON MONOXIDE IN PRESENCE OF COBALT,IODINE AND PHOSPHORUS COMPOUND | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-11-30 | — | — | US | disclosed |
| US-4352947-A | METHANOL; CARBON MONOXIDE; HYDROGEN; COBALT; IODINE; RUTHENIUM; AND PHOSPHORUS, NITROGEN, OR ARSENIC LIGAND | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-10-05 | — | — | US | disclosed |
| US-4292232-A | Process for the mass coloration of thermoplastics with anthraquinonylaminotraizines | CIBA-GEIGY CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115824-A1 | Vitamin D Receptor Agonists and Uses Thereof | VDR, CYP2R1, CYP24A1 | ATM 2604/4885CES2 4701/4885CES1 2107/4885 |
| US-20180327354-A1 | Unnatural Analogues of Calcitriol and Uses Thereof | VDR, CYP2R1, CYP24A1 | ATM 3977/4885CES2 4566/4885CES1 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.